BlackRock’s Bluejay Diagnostics BJDX Stock Holding History

BlackRock’s Portfolio BJDX Stock Details BJDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	-$23K	–	5854
2022 Q1	$23K	Buy	+1	New	+$48.2K	﹤0.01%	5542
2021 Q4	–	Hold	0	–	–	–	5595

Other funds holding BJDX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock's BJDX Position: Q2 2022 in Review

BlackRock sold out of Bluejay Diagnostics (BJDX) in Q2 2022, closing a stake of 1 share — an estimated $23K sold.

BlackRock first reported a position in BJDX in Q1 2022 and held it in 1 quarter. The position peaked at $23K in Q1 2022. 6 funds tracked by Wall St. Rank hold BJDX as of Q2 2022.

BlackRock reported no remaining Bluejay Diagnostics position as of Q2 2022 after selling out during the quarter.
BlackRock sold 1 Bluejay Diagnostics share in Q2 2022, an estimated $23K.
BlackRock first reported a position in Bluejay Diagnostics in Q1 2022 and held it in 1 quarter.
BlackRock's Bluejay Diagnostics position peaked at $23K in Q1 2022.
6 funds tracked by Wall St. Rank held Bluejay Diagnostics as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.